Galderma’s First-In-Class Biologic Chases Eczema Spoils
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
You may also be interested in...
The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.